CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis

作者：Canyu Liu, Qiujun Liu, Yuanhao Lv, Tingmin Chang, Shiyi Song, Yuang Ding, Jiateng Zhong, Yanxuan Liu · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2025.1589423 · 被引用次数：1 · 研究领域：Ferroptosis and cancer prognosis、Cancer Immunotherapy and Biomarkers、Immune cells in cancer

Background: Colorectal cancer (CRC) remains a predominant contributor to cancer-related mortality globally, with its resistance to immunotherapeutic strategies presenting a formidable challenge in patient management. Recent investigations have illuminated the prospective involvement of ferroptosis, a regulated form of cell death, in both cancer progression and the development of resistance to therapeutic interventions. Objective: This study aims to elucidate the prognostic significance of CPLX1 in CRC, specifically its correlation with immunotherapy resistance and its association with ferroptosis, thereby contributing to a deeper understanding of tumor biology and therapeutic vulnerability. Methods: We conducted an integrative analysis of RNA-seq datasets from the TCGA-COAD and TCGA-READ projects, along with the GEO GSE156451 dataset, to discern differentially expressed genes. Expression levels of CPLX1 were evaluated utilizing the TIMER 2.0 database, and survival analyses were performed via Kaplan-Meier plots and Cox regression modeling to assess prognostic implications. Additionally, mutational analyses through cBioPortal and COSMIC datasets were employed to identify CPLX1 mutations in COAD. Co-expression and functional enrichment analyses, alongside Gene Set Enrichment Analysis (GSEA), were also conducted to delineate pathways impacted by CPLX1. Results: Our findings indicate that high expression levels of CPLX1 are significantly correlated with poor prognostic outcomes in...